Table 1.
General characteristics of the study population.
| Control |
PWH |
Overall |
|
|---|---|---|---|
| (N = 12) | (N = 24) | (N = 36) | |
| Age (years) | |||
| Median [Min, Max] | 48.5 [28.0, 67.0] | 46.9 [24.5, 69.4] | 47.6 [24.5, 69.4] |
| Sex (N, %) | |||
| Female | 7 (58.3%) | 2 (8.3%) | 9 (25.0%) |
| Male | 5 (41.7%) | 22 (91.7%) | 27 (75.0%) |
| Body Mass Index (kg/height(m^2)) | |||
| Mean (SD) | 24.4 (3.65) | 25.3 (3.85) | 25.0 (3.75) |
| Recent antibiotic use | |||
| No | 12 (100%) | 24 (100%) | 36 (100%) |
| Recent antifungal use | |||
| No | 12 (100%) | 24 (100%) | 36 (100%) |
| No | 12 (100%) | 24 (100%) | 36 (100%) |
| HIV-related variables | |||
| Years since HIV diagnosis | |||
| Median (25th-75th percentile) | - | 6.5 (2.9–18.4) | - |
| Nadir CD4 + T cells/uL | |||
| Median (25th-75th percentile) | - | 218 (105–294) | - |
| CD4 + T cells (counts/uL) | |||
| Median (25th-75th percentile) | - | 555.8 (456, 695) | - |
| Baseline HIV RNA (log 10 copies/mL) | |||
| Median (25th-75th percentile) | 4.9 (4.2–5.5) | ||
| Undetectable HIV RNA (N, %) | 24 (100%) | ||
| Antiretroviral therapy (N, %) | |||
| INSTI-based | 8 (33.4) | ||
| PI-based | 1 (4.1) | ||
| NNRTI-based | 15 (62.5) | ||
Abbreviatures: INSTI, integrase strand-transfer inhibitors; PI, protease inhibitors; NNRTI, non-nucleoside retrotranscriptase inhibitors.